As filed with the Securities and Exchange Commission on August 18, 1997
                                          Registration No. 33-


                    SECURITIES AND EXCHANGE COMMISSION
                          WASHINGTON, D.C. 20549


                                 FORM S-8


                          REGISTRATION STATEMENT
                                  UNDER
                        THE SECURITIES ACT OF 1933


                     REGENERON PHARMACEUTICALS, INC.
          ------------------------------------------------------
          (Exact name of registrant as specified in its charter)


              NEW YORK                             13-3444607
       ------------------------      ------------------------------------
       (State of incorporation)      (I.R.S. employer identification no.)


                       777 Old Saw Mill River Road
                        Tarrytown, New York 10591
                 ----------------------------------------
                 (Address of principal executive offices)


                     REGENERON PHARMACEUTICALS, INC.
                      1990 LONG-TERM INCENTIVE PLAN
                     -------------------------------
                         (Full title of the plan)


   Paul Lubetkin, Esq., Vice President, General Counsel, and Secretary
                     Regeneron Pharmaceuticals, Inc.
                       777 Old Saw Mill River Road
                        Tarrytown, New York 10591
                              (914) 347-7000
        ---------------------------------------------------------
        (Name, address and telephone number, including area code,
                          of agent for service)


                                Copies to:

                         Matthew J. Mallow, Esq.
                   Skadden, Arps, Slate, Meagher & Flom
                             919 Third Avenue
                         New York, New York 10022
                             (212) 735-3000



                                  CALCULATION OF REGISTRATION FEE
====================================================================================================== Proposed Maximum Proposed Maximum Amount of Title of Securities Amount to be Offering Price Aggregate Offering Registration to be Registered Registered Per Share (1)(2) Price (2) Fee =================================================================================================== Common Stock, par value $0.001 per share 1,500,000 shares $9.375 $14,062,500 $4,489 =================================================================================================== (1) Estimated pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act of 1933, as amended, on the basis of the average of the high and low sale prices for a share of Common Stock on Nasdaq National Market on September 15, 1995, within five business days prior to filing. (2) Estimated solely for the purpose of calculating the registration fee. ===================================================================================================
REGISTRATION STATEMENT FOR REGISTRATION OF ADDITIONAL SECURITIES ON FORM S-8 Incorporation by Reference -------------------------- Hereby incorporated by reference is Registrant's Registration Statement on Form S-8 (No. 33-50480) filed on August 5, 1992 with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Exchange Act of 1934, as amended (the "Securities Act"). Required Information Not in Prior Statement ------------------------------------------- Not Applicable. SIGNATURES Pursuant to the requirements of the Securities Act, Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tarrytown, State of New York, on the 18th day of August, 1997. REGENERON PHARMACEUTICALS, INC. By * -------------------------------------- Leonard S. Schleifer, M.D., Ph.D. President and Chief Executive Officer Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on August 18, 1997. Signature Title --------- ----- * - --------------------------------- Chairman of the Board of Directors P. Roy Vagelos, M.D. * - --------------------------------- President, Chief Executive Officer Leonard S. Schleifer, M.D., Ph.D. (Principal Executive Officer), and Director * - --------------------------------- Vice President, Finance & Murray A. Goldberg Administration, Chief Financial Officer, and Treasurer (Principal Financial Officer) * - --------------------------------- Controller and Assistant Treasurer Beverly C. Dubs (Chief Accounting Officer) * - --------------------------------- Director Charles A. Baker * - --------------------------------- Director Michael S. Brown, M.D. * - --------------------------------- Director Alfred G. Gilman, M.D., Ph.D. * - --------------------------------- Director Joseph L. Goldstein, M.D. * - --------------------------------- Director Fred A. Middleton * - --------------------------------- Director Eric M. Shooter, M.D. * - --------------------------------- Director George L. Sing *By: /s/ PAUL LUBETKIN - --------------------------------- Paul Lubetkin (Attorney-in-fact) LIST OF EXHIBITS Designation Description of Exhibit - ----------- ---------------------- 4.1 Registrant's Articles of Incorporation (incorporated by reference to Registrant's Quarterly Report on Form 10-Q for its quarter ended June 30, 1991, filed with the Commission on August 13, 1991). 4.2 Registrant's By-Laws (incorporated by reference to Registrant's Annual Report on Form 10-K for its year ended December 31, 1994, filed with the Commission on March 31 , 1995). 5 Opinion of Skadden, Arps, Slate, Meagher & Flom. 23.1 Consent of Coopers & Lybrand L.L.P. (for the Registrant). 23.2 Consent of Ernst & Young LLP (for Amgen-Regeneron Partners). 23.3 Consent of Skadden, Arps, Slate, Meagher & Flom (contained in Exhibit 5). 24 Power of Attorney

                                                          EXHIBIT 5


           [SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Lettherhread]


                                        August 18, 1997


          Regeneron Pharmaceuticals, Inc.
          777 Old Saw Mill River Road
          Tarrytown, New York  10591

          Gentlemen:

                    We have acted as special counsel to Regeneron
          Pharmaceuticals, Inc., a New York corporation (the
          "Company"), in connection with the proposed issuance by
          the Company of 1,500,000 shares (the "Shares") of Common
          Stock, par value $.001 per share (the "Common Stock"),
          pursuant to the Regeneron Pharmaceuticals, Inc. Amended
          and Restated 1990 Long Term Incentive Plan (the "Stock
          Option Plan").

                    This opinion is delivered in accordance with
          the requirements of Item 601(b)(5) of Regulation S-K
          under the Securities Act of 1933, as amended (the
          "Securities Act").

                    In connection with this opinion, we have
          examined and are familiar with originals or copies,
          certified or otherwise identified to our satisfaction, of
          (i) the Registration Statement on Form S-8, relating to
          the Shares, filed with the Securities and Exchange
          Commission (the "Commission") under the Securities Act on
          August 18, 1997 (together with all exhibits thereto, the
          "Registration Statement"), (ii) the Restated Certificate
          of Incorporation of the Company as currently in effect,
          (iii) the By-Laws of the Company as currently in effect,
          (iv) specimen certificates representing the Shares, and
          (v) resolutions of the Board of Directors of the Company
          relating to the Stock Option Plan and the filing of the
          Registration Statement.  We have also examined originals
          or copies, certified or otherwise identified to our
          satisfaction, of such records of the Company and such
          agreements, certificates of public officials,
          certificates of officers or other representatives of the
          Company and others, and such other documents,
          certificates and records, as we have deemed necessary or
          appropriate as a basis for the opinions set forth herein.

                    In our examination, we have assumed the legal
          capacity of all natural persons, the genuineness of all
          signatures, the authenticity of all documents submitted
          to us as originals, the conformity to original documents
          of all documents submitted to us as certified or
          photostatic copies and the authenticity of the originals
          of such latter documents.  In making our examination of
          documents executed or to be executed by parties other
          than the Company, we have assumed that such parties had
          the power, corporate or other, to enter into and perform
          all obligations thereunder and have also assumed the due
          authorization by all requisite action, corporate or
          other, and execution and delivery by such parties of such
          documents and the validity and binding effect thereof. 
          As to any facts material to the opinions expressed herein
          which we have not independently established or verified,
          we have relied upon oral or written statements and
          representations of officers and other representatives of
          the Company and others.

                    Members of our firm are admitted to the Bar in
          the State of New York and we do not express any opinion
          as to the laws of any other jurisdiction.

                    Based upon and subject to the foregoing, we are
          of the opinion that the Shares to be issued upon exercise
          of any options duly granted pursuant to the terms of the
          Stock Option Plan have been duly and validly authorized
          and, when the Shares have been issued, delivered and paid
          for, upon exercise of such options in accordance with the
          terms of the Stock Option Plan and certificates
          representing the Shares in the form of the specimen
          certificates examined by us have been manually signed by
          an authorized officer of the transfer agent and registrar
          for the Common Stock and registered by such transfer
          agent and registrar, such Shares will be duly and validly
          issued, fully paid and nonassessable (except as provided
          in Section 630 of the New York Business Corporation Law).

                    We hereby consent to the filing of this opinion
          with the Commission as Exhibit 5 to the Registration
          Statement.  In giving such consent, we do not thereby
          admit that we are included in the category of persons
          whose consent is required under Section 7 of the
          Securities Act.

                                   Very truly yours,

                                   /s/ Skadden, Arps, Slate,
                                         Meagher & Flom LLP


                                                       EXHIBIT 23.1


                     CONSENTS OF INDEPENDENT ACCOUNTANTS

                    We consent to the incorporation by reference in
          this Registration Statement of Regeneron Pharmaceuticals,
          Inc. (the "Company") on Form S-8 of our report dated
          February 14, 1997, on our audits of the financial
          statements of the Company as of December 31, 1996, and
          1995, and for each of the three years in the period ended
          December 31, 1996, which report is included in the
          Company's Annual Report on Form 10-K for the year ended
          December 31, 1996.

                                   /s/ Coopers & Lybrand L.L.P.

          New York, New York
          August 14 , 1997




                                                       EXHIBIT 23.2

             CONSENT OF ERNEST & YOUNG LLP, INDEPENDENT AUDITORS

                    We consent to the incorporation by reference in
          this Registration Statement on Form S-8 pertaining to the
          Regeneron Pharmaceuticals, Inc. Amended and Restated 1990
          Long Term Incentive Plan, of our report dated February 5,
          19967, with respect to the financial statements of Amgen-
          Regeneron Partners included in Regeneron Pharmaceuticals,
          Inc's Annual Report (Form 10-K) for the year ended
          December 31, 1996, filed with the Securities and Exchange
          Commission.

                                      /s/ ERNST & YOUNG LLP

          Los Angeles, California
          August 14, 1997





                                                  EXHIBIT 24


                             POWER OF ATTORNEY

               We, the undersigned officers and directors of Regeneron
     Pharmaceuticals, Inc., hereby severally and individually
     constitute and appoint Paul Lubetkin the true and lawful attorney
     and agent (with full power of substitution and resubstitution in
     each case) of each of us to execute in the name, place and stead
     of each of us (individually and in any capacity stated below) the
     Registration Statement on Form S-8 dated August 18, 1997 and all
     instruments necessary or advisable in connection therewith and to
     file the same with the Securities and Exchange Commission, said
     attorney and agent to have power to act and to have full power
     and authority to do and perform in the name and on behalf of each
     of the undersigned every act whatsoever necessary or advisable to
     be done in the premises as fully and to all intents and purposes
     as any of the undersigned might or could do in person, and we
     hereby ratify and confirm our signatures as they may be signed by
     our said attorney and agent to any and all such statement and
     instruments.

               This Power of Attorney has been signed below by the
     following persons in the capacities indicated on August 18, 1997.
     
     
               Signature                 Title

     /s/  P. ROY VAGELOS                 Chairman of the Board of Directors 
     ____________________________
     P. Roy Vagelos, M.D.                

     /s/  LEONARD S. SCHLEIFER           President, Chief Executive
     ____________________________        Officer (Principal Executive
     Leonard S. Schleifer, M.D., Ph.D.   Officer), and Director
     

     /s/  MURRAY A. GOLDBERG             Vice President, Finance &
     _____________________________       Administration, Chief 
     Murray A. Goldberg                  Financial Officer, and
                                         Treasurer (Principal
                                         Financial Officer)

     /s/  BEVERLY C. DUBS                Controller and Assistant
     ______________________________      Treasurer (Chief Accounting
     Beverly C. Dubs                     Officer)

     /s/  CHARLES A. BAKER               Director
     _______________________________   
     Charles A. Baker

     /s/  MICHAEL S. BROWN               Director
     _______________________________
     Michael S. Brown, M.D

     /s/  ALFRED G. GILMAN               Director
     _______________________________
     Alfred G. Gilman, M.D., Ph.D.

     /s/  JOSEPH L. GOLDSTEIN            Director
     _______________________________
     Joseph L. Goldstein, M.D.

     /s/  FRED A. MIDDLETON              Director
     _______________________________
     Fred A. Middleton

     /s/  ERIC M. SHOOTER                Director
     _______________________________
     Eric M. Shooter, M.D.

     /s/  GEORGE L. SING                 Director
     _______________________________
     George L. Sing